Introduction
Materials and methods
Study design and setting
Participants, recruitment and informed consent
Data analysis
Results
The multidisciplinary steering group
Audience, scope, purpose and format
Exploratory evidence review
Needs-assessment: online surveys
Questions / statements | Patients | Clinicians |
---|---|---|
An online PtDA to help patients make treatment modality decision for kidney failure seems* | Very unhelpful = 6 (5%) Unhelpful = 10 (8%) Neutral = 36 (29%) Helpful = 49 (39%) Very helpful = 24 (19%) | Very unhelpful = 0 (0%) Unhelpful = 0 (0%) Neutral = 5 (16%) Helpful = 21 (66%) Very helpful = 6 (19%) |
A detailed description of all treatment modalities for kidney failure should be included in the PtDA* | Yes = 94 (75%) No = 29 (23%) I don’t know = 2 (2%) | Yes = 28 (88%) No = 4 (12% I don’t know = 0 (0%) |
Information regarding the pros and cons of each treatment modality should be included in the PtDA* | Yes = 107 (85%) No = 16 (13%) I don’t know = 2 (2%) | Yes = 28 (88%) No = 4 (12%) I don’t know = 0 (0%) |
Stories and experiences of peer patients on the treatment modalities should be included in the PtDA* | Yes = 44 (35%) No = 79 (63%) I don’t know = 2 (2%) | Yes = 23 (72%) No = 9 (28%) I don’t know = 0 (0%) |
Medical outcome information* (such as complication rates, hospitalisation) should be included in the PtDA | Yes = 79 (63%) No = 44 (35%) I don’t know = 2 (2%) | Yes = 23 (72%) No = 9 (28%) I don’t know = 0 (0%) |
Patient reported outcome information* (such as pain, fatigue, physical functioning) should be included in the PtDA | Yes = 60 (48%) No = 63 (50%) I don’t know = 2 (2%) | Yes = 25 (78%) No = 7 (22%) I don’t know = 0 (0%) |
Effects of the treatment modalities on social functioning and personal life* (such as being able to work, travel or do hobbies) should be included in the PtDA | Yes = 85 (68%) No = 38 (30%) I don’t know = 2 (2%) | Yes = 31 (97%) No = 1 (3%) I don’t know = 0 (0%) |
Ranked usability of treatment outcomes for treatment modality decision making according to patients 1 = highest, 15 = lowest | Results |
---|---|
1.The flexibility of each treatment modality* | Yes = 93 (74%) No = 20 (16%) I don’t know = 12 (10%) |
2.The survival of each treatment modality after treatment initiation* | Yes = 92 (74%) No = 11 (9%) I don’t know = 21 (17%) |
3.The effect of each treatment modality on the residual kidney function over time* | Yes = 89 (71%) No = 19 (15%) I don’t know = 17 (14%) |
4.Patient reported levels of physical functioning on each treatment modality* | Yes = 82 (66%) No = 30 (24%) I don’t know = 13 (10%) |
5.The effects of each treatment modality on social functioning* | Yes = 81 (65%) No = 31 (25%) I don’t know = 12 (10%) |
6.Patient survival on each treatment modality* | Yes = 81 (65%) No = 27 (22%) I don’t know = 17 (13%) |
7.The effects of each treatment modality on personal life* | Yes = 78 (63%) No = 33 (27%) I don’t know = 13 (10%) |
8.Complication rates related to immunosuppressive drugs after transplantation* | Yes = 76 (61%) No = 34 (27%) I don’t know = 15 (12%) |
9.Hospitalisation rates for each treatment modality after initiation* | Yes = 74 (60%) No = 36 (29%) I don’t know = 14 (11%) |
10.Event rates for cardiovascular complications on each treatment modality* | Yes = 73 (58%) No = 29 (24%) I don’t know = 23 (18%) |
11.Patient reported levels of pain on each treatment modality* | Yes = 67 (54%) No = 43 (35%) I don’t know = 14 (11%) |
12.Vascular access survival in HD* | Yes = 67 (54%) No = 35 (28%) I don’t know = 23 (18%) |
13.Patient reported levels of fatigue on each treatment modality* | Yes = 66 (53%) No = 40 (32%) I don’t know = 19 (15%) |
14.PD peritonitis rates* | Yes = 64 (52%) No = 41 (33%) I don’t know = 18 (15%) |
15.Patient reported levels of depression on each treatment modality* | Yes = 54 (43%) No = 54 (43%) I don’t know = 17 (14%) |
Needs-assessment: focus groups
Outcome information
The ‘Kidney Failure Decision Aid’ prototype
Alpha testing
Topic | Needs and preferences | |
---|---|---|
Patients and Caregiver | Clinicians | |
Education and decision-making | Don’t forget the person behind the patient* Clearly define the patient journey and take the lead as primary practitioner* Provide mentorship and guidance throughout the educational and decision-making process* | Coordinate with colleagues and adjust the education based on the educational needs of patients* Evaluate how well patients understand the provided information* Explore how patients make their choices, and who was involved in the decision-making process* |
SDM | Strive for an equal patient-physician relationship* Facilitate patients in preference elicitation and values-clarification* Explicitly communicate when the decision has to be made* | Explicitly communicate that the opinions and wishes of patients are important in the decision* Do not try to “sell” any treatment modality, even if they have superior medical outcomes* |
Online PtDA | Exercise caution for “informational overload”* Strive for collaboration and integrate everything on one platform* | Consider clinical practice when designing the PtDA* Pay attention to culture and health literacy* |
Outcome information | Give patients autonomy in viewing outcome information* Provide tailored outcome information when possible* | Provide guidance on the interpretation of treatment outcomes* Pay attention to data visualization* |
Topic | Needs and preferences identified in focus groups | Incorporated in the PtDA? |
---|---|---|
Education and decision-making | Don’t forget the person behind the patient* | Paper hand-out sheet, interactive website and summary sheet contain components that facilitate conversation on the personal situation, wishes, and preferences of patients |
Clearly define the patient journey and take the lead as primary practitioner* | Paper hand-out sheet contains a flowchart of the advanced CKD care pathway Interactive website contains a chapter with information on all involved clinicians, and when the decision has to be made | |
Provide mentorship and guidance throughout the educational and decision-making process* | Paper hand-out sheet, interactive website, and summary sheet contain components that guide patients and clinicians in making values and preference-based decisions | |
Coordinate with colleagues and adjust the education based on patients’ educational needs* | No | |
Evaluate how well patients understand the provided information* | No | |
Explore how patients make their choices, and who was involved in the decision-making process* | Interactive website and summary sheet contain components that facilitate conversations on who plays an important role in making decisions | |
SDM | Strive for an equal patient-physician relationship* | Paper hand-out sheet, interactive website, and summary sheet explicitly mention that the decision should be made according to the principles of SDM |
Facilitate patients in preference elicitation and values-clarification* | Paper hand-out sheet, interactive website and summary sheet contain components that facilitate conversation on the personal situation, wishes, and preferences of patients Paper hand-out sheet, interactive website, and summary sheet contain components that guide patients in values-clarification and preference-elicitation | |
Explicitly communicate when the decision has to be made* | Paper hand-out sheet contains a flowchart of the advanced CKD care pathway Interactive website contains a chapter with information on all involved clinicians, and when the decision has to be made | |
Explicitly communicate that the opinions and wishes of patients are important in the decision* | Paper hand-out sheet, interactive website, and summary sheet explicitly mention that the decision should be made according to the principles of SDM | |
Do not try to “sell” any treatment modality, even if they have superior medical outcomes* | Paper hand-out sheet, interactive website, and summary sheet explicitly mention that the decision should be made according to the principles of SDM | |
Online PtDA | Exercise caution for “informational overload”* | Paper hand-out sheet contains elements that provide guidance on what chapters of the interactive website patients should focus on most Interactive website allows for easy navigation between chapters, saves patients’ location and answers when logging off, and provides the educational content in similarly structured chapters |
Strive for collaboration, and integrate everything on one platform* | PtDA has been developed in collaboration with key stakeholders and contains educational content of nieren.nl and nierwijzer.nl, both of which are owned by the Dutch kidney patient association and are endorsed by nephrology clinicians in the Netherlands | |
Consider clinical practice when designing the PtDA* | PtDA has been developed for integration in established healthcare pathways without interfering with routine procedures | |
Pay attention to health literacy and culture* | All components of the PtDA have been written in the B1 level of the CEFRL | |
Outcome information | Give patients autonomy in viewing outcome information* | Patients have to actively click through disclaimers before viewing survival probabilities and hospitalisation rates |
Provide tailored outcome information when possible* | Survival probabilities and hospitalisation rates have been stratified in age categories used by Dutch dialysis and kidney transplantation data registries | |
Provide guidance on the interpretation of treatment outcomes* | Interactive website provides information on how patient characteristics impact treatment outcomes, and encourages conversations on treatment outcomes between patient and clinicians | |
Pay attention to data visualization* | Outcome information has been visualised with infographics when possible |
Beta testing
Finalising the ‘Kidney Failure Decision Aid’
Implementation
-
An introductory session for clinicians about SDM and using outcome information to support this process;
-
Two e-learning courses about SDM and outcome information (“SDM with patients”, and “Applying outcome information in SDM”) for clinicians;
-
In-person education and conversational skills training (“Conversational skills for SDM and the use of outcome information) for clinicians, during which they are thought and practice (with actors) conversational skills to successfully engage their patients in SDM and support this process with outcome information;
-
Collaborating with clinicians to integrate the PtDA in local care pathways;
-
Kick-off meetings to plan a formal ‘launch’ date and instruct clinicians on how to use the PtDA;
-
Offering centralized implementation support and technical assistance for clinicians and patients;
-
Assigning ‘local ambassadors’ to closely monitor progress and stimulate implementation through an implementation dashboard;
-
A post-launch ‘refresher’ e-learning (“conversational skills for SDM and the use of outcome information”) for clinicians on the taught conversational skills.